Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00558012 · ClinicalTrials.gov registry record · NA
Zoledronic Acid for Osteoporosis in the Elderly
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 181
- Enrollment target
NCT00558012: Completed NA study, sponsored by University of Pittsburgh.
NCT00558012 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 181 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00558012, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 181 participants
- Enrollment target
Study Summary
This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.
Primary Outcome
BMD is the bone mineral density of the lumbar spine and total hip measured using dual-energy xray absorptiometry (DXA) scan
Interventions
- DRUG Intravenous zoledronic acid
- DIETARY_SUPPLEMENT Vitamin D 800 IU/daily
- DIETARY_SUPPLEMENT Calcium 1200 mg/daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2007-12 |
| Est. Completion | 2014-02 |
| Phase | NA |
What the finished NCT00558012 record still lists
NCT00558012 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Intravenous zoledronic acid is the first listed.
NCT00558012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00558012 about?
NCT00558012 is a clinical study titled "Zoledronic Acid for Osteoporosis in the Elderly". This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that...
What is the current status of trial NCT00558012?
This trial is currently completed. It is a NA study. The enrollment target is 181 participants. The study started on 2007-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00558012?
The interventions under investigation include: Intravenous zoledronic acid (DRUG), Vitamin D 800 IU/daily (DIETARY_SUPPLEMENT), Calcium 1200 mg/daily (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00558012?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00558012's enrollment target sits among peer trials
181 586th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia